Alpha Teknova, Inc. (TKNO) stock
TKNONasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/30124% above fair value
$7.65−0.12 (-1.54%)
Close on Nov 17, 2026Market cap $410.72MP/E –Yield –
Alpha Teknova revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Alpha Teknova's revenue for the twelve months ending Jun 30, 2026 was $43.70M, up 12.3% year over year. For fiscal 2025 it was $40.52M, up 7.4% from the year before. The highest annual figure on record is $41.42M in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.52M | +7.4% |
| FY2024 | Dec 31, 2024 | $37.75M | +2.9% |
| FY2023 | Dec 31, 2023 | $36.68M | -11.4% |
| FY2022 | Dec 31, 2022 | $41.42M | +12.3% |
| FY2021 | Dec 31, 2021 | $36.89M | +17.9% |
| FY2020 | Dec 31, 2020 | $31.30M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $12.19M | +18.5% |
| Q1 FY2026 | Mar 31, 2026 | $11.08M | +13.1% |
| Q4 FY2025 | Dec 31, 2025 | $9.98M | +7.8% |
| Q3 FY2025 | Sep 30, 2025 | $10.45M | +9.2% |
| Q2 FY2025 | Jun 30, 2025 | $10.29M | +7.0% |
| Q1 FY2025 | Mar 31, 2025 | $9.80M | +5.4% |
| Q4 FY2024 | Dec 31, 2024 | $9.27M | +17.8% |
| Q3 FY2024 | Sep 30, 2024 | $9.58M | +17.2% |
| Q2 FY2024 | Jun 30, 2024 | $9.61M | -16.6% |
| Q1 FY2024 | Mar 31, 2024 | $9.29M | +1.9% |
| Q4 FY2023 | Dec 31, 2023 | $7.87M | -0.3% |
| Q3 FY2023 | Sep 30, 2023 | $8.17M | -23.6% |
| Q2 FY2023 | Jun 30, 2023 | $11.53M | -1.4% |
| Q1 FY2023 | Mar 31, 2023 | $9.12M | -18.2% |
| Q4 FY2022 | Dec 31, 2022 | $7.89M | -21.9% |
| Q3 FY2022 | Sep 30, 2022 | $10.69M | +13.8% |
| Q2 FY2022 | Jun 30, 2022 | $11.69M | +40.6% |
| Q1 FY2022 | Mar 31, 2022 | $11.15M | +22.8% |
| Q4 FY2021 | Dec 31, 2021 | $10.11M | -0.5% |
| Q3 FY2021 | Sep 30, 2021 | $9.39M | +4.5% |
| Q2 FY2021 | Jun 30, 2021 | $8.31M | +37.5% |
| Q1 FY2021 | Mar 31, 2021 | $9.08M | – |
| Q4 FY2020 | Dec 31, 2020 | $10.16M | – |
| Q3 FY2020 | Sep 30, 2020 | $8.98M | – |
| Q2 FY2020 | Jun 30, 2020 | $6.04M | – |
See a number that looks wrong?